Amryt Pharma Holdings Limited, often referred to simply as Amryt Pharma, is a prominent biopharmaceutical company headquartered in Great Britain. Founded in 2015, the company has rapidly established itself within the global pharmaceutical industry, focusing on innovative treatments for rare and complex diseases. Amryt Pharma's core business areas include the development of therapies for dermatological conditions and metabolic disorders, with a particular emphasis on rare diseases. Their flagship products, such as AP101 for epidermolysis bullosa, highlight the company's commitment to addressing unmet medical needs through unique and effective solutions. With a strong market position, Amryt Pharma has achieved significant milestones, including successful product launches and strategic partnerships, solidifying its reputation as a leader in the rare disease space.
We don't have data for Amryt Pharma Holdings Limited, but we can show you information about their parent organization instead.
View parent company